Pertuzumab Retreatment Extends Survival in HER2-Positive Breast Cancer by 10 Months

The PRECIOUS study provides compelling evidence that retreating HER2-positive metastatic breast cancer patients with pertuzumab can extend survival, even after they've previously progressed on pertuzumab-containing regimens. This challenges conventional thinking about drug resistance in cancer treatment.

This Japanese phase III trial randomized 219 patients with HER2-positive locally advanced or metastatic breast cancer who had previously received pertuzumab-based therapy. Patients were assigned to receive either pertuzumab plus trastuzumab with chemotherapy (PTC group) or trastuzumab with chemotherapy alone (TC group). All patients had progressed on prior pertuzumab treatment, making this a true test of retreatment efficacy.

The results were striking: median overall survival reached 36.2 months in the PTC group versus 26.5 months in the TC group—a nearly 10-month improvement. The hazard ratio of 0.73 indicates a 27% reduction in death risk with pertuzumab retreatment. Updated progression-free survival also favored the combination (5.5 versus 4.2 months), though independent review showed no difference.

These findings have immediate clinical implications. Current guidelines recommend continuing anti-HER2 therapy after progression, but evidence for dual blockade retreatment was limited. This study provides robust data supporting pertuzumab retreatment in appropriate patients. The survival benefit suggests that cancer cells don't develop permanent resistance to pertuzumab, and that dual HER2 blockade retains meaningful activity even after prior exposure.

The study was conducted across 93 Japanese institutions with rigorous methodology, though the open-label design and investigator-assessed endpoints introduce some limitations. The discrepancy between investigator and independent review for progression-free survival warrants consideration, but the overall survival benefit—the gold standard endpoint—remains compelling.